The latest announcement is out from Ocugen ( (OCGN) ).

Ocugen’s Breakthrough: A Game Changer For Treatment? Ocugen this week reported encouraging interim results from its Phase 2 ArMaDa trial of OCU410 for geographic atrophy, showing a 46% reduction in ...

Shares of Ocugen Inc. OCGN advanced 2.90% to $1.42 Tuesday, on what proved to be an all-around mixed trading session for the ...

The average one-year price target for Ocugen (NasdaqCM:OCGN) has been revised to $8.36 / share. This is an increase of 26.15% from the prior estimate of $6.63 dated September 27, 2025. The price ...

Shares of Ocugen, Inc. (NASDAQ:OCGN) fell 6.6% in premarket trading on Wednesday after the biotech group announced the pricing of an underwritten common stock offering. Ocugen said it will issue 15 ...

Ocugen OCGN is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms of action. With all three key pipeline programs moving on schedule, Ocugen ...

Ocugen Inc. closed 29.59% below its 52-week high of $1.96, which the company achieved on January 14th.

Johnson-Greene has more than 20 years of healthcare experience. She most recently served as Chief Operating Officer at the Alliance for Regenerative Medicine (ARM) where she led ARM's operations, ...